Role of Type 1 IFNs in Antiglioma Immunosurveillance—Using Mouse Studies to Guide Examination of Novel Prognostic Markers in Humans

Purpose: We hypothesized that the type 1 IFNs would play a pivotal role in antiglioma immunosurveillance through promotion of type 1 adaptive immunity and suppression of immunoregulatory cells. Experimental Design: We induced de novo gliomas in Ifnar1−/− (deficient for type 1 IFN receptors) or wild-type mice by intracerebroventricuar transfection of NRas and a short hairpin RNA against P53 using the Sleeping Beauty transposon system. We analyzed the survival of 587 glioma patients for single nucleotide polymorphisms (SNP) in type 1 IFN–related genes. Results: Ifnar1−/− mice exhibited accelerated tumor growth and death. Analyses of brain tumor–infiltrating lymphocytes in Ifnar1−/− mice revealed an increase of cells positive for CD11b+Ly6G+ and CD4+FoxP3+, which represent myeloid-derived suppressor cells and regulatory T cells, respectively, but a decrease of CD8+ cytotoxic T lymphocytes (CTLs) compared with wild-type mice. Ifnar1−/− mouse–derived glioma tissues exhibited a decrease in mRNA for the CTL-attracting chemokine Cxcl10, but an increase of Ccl2 and Ccl22, both of which are known to attract immunoregulatory cell populations. Dendritic cells generated from the bone marrow of Ifnar1−/− mice failed to function as effective antigen-presenting cells. Moreover, depletion of Ly6G+ cells prolonged the survival of mice with developing gliomas. Human epidemiologic studies revealed that SNPs in IFNAR1 and IFNA8 are associated with significantly altered overall survival of patients with WHO grade 2 to 3 gliomas. Conclusions: The novel Sleeping Beauty–induced murine glioma model led us to discover a pivotal role for the type 1 IFN pathway in antiglioma immunosurveillance and relevant human SNPs that may represent novel prognostic markers. Clin Cancer Res; 16(13); 3409–19. ©2010 AACR.

[1]  J. Berzofsky,et al.  Synergistic Enhancement of CD8+ T Cell–Mediated Tumor Vaccine Efficacy by an Anti–Transforming Growth Factor-β Monoclonal Antibody , 2009, Clinical Cancer Research.

[2]  R. Vonderheide,et al.  Clinical Use of Anti‐CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells , 2009, Annals of the New York Academy of Sciences.

[3]  Benjamin Purow,et al.  Advances in the genetics of glioblastoma: are we reaching critical mass? , 2009, Nature Reviews Neurology.

[4]  B. Rini,et al.  Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients , 2009, Clinical Cancer Research.

[5]  I. Parney,et al.  Flow cytometry and in vitro analysis of human glioma-associated macrophages. Laboratory investigation. , 2009, Journal of neurosurgery.

[6]  Simon C Watkins,et al.  Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10. , 2009, Cancer research.

[7]  D. Largaespada,et al.  De novo induction of genetically engineered brain tumors in mice using plasmid DNA. , 2009, Cancer research.

[8]  Edward R. Kastenhuber,et al.  Immunotherapeutic approaches for glioma. , 2009, Critical reviews in immunology.

[9]  Y. Marie,et al.  Polymorphism in the microglial cell-mobilizing CX3CR1 gene is associated with survival in patients with glioblastoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  K. Aldape,et al.  Polymorphisms in the Interleukin-4 Receptor Gene are Associated with Better Survival in Patients with Glioblastoma , 2008, Clinical Cancer Research.

[11]  G. Parmigiani,et al.  Toll-like receptor 3 and geographic atrophy in age-related macular degeneration. , 2008, The New England journal of medicine.

[12]  D. Bartlett,et al.  Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. , 2008, Cancer research.

[13]  R. Vierkant,et al.  Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. , 2008, Vaccine.

[14]  I. Pollack,et al.  Inhibition of STAT3 Promotes the Efficacy of Adoptive Transfer Therapy Using Type-1 CTLs by Modulation of the Immunological Microenvironment in a Murine Intracranial Glioma1 , 2008, The Journal of Immunology.

[15]  Michael D. Connolly,et al.  Use of Ly6G‐specific monoclonal antibody to deplete neutrophils in mice , 2008, Journal of leukocyte biology.

[16]  Susan M. Chang,et al.  A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05) , 2008, Journal of Neuro-Oncology.

[17]  Susan M. Chang,et al.  A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas , 2008, Journal of Neuro-Oncology.

[18]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[19]  Paul J. Hertzog,et al.  Type I Interferon Receptors: Biochemistry and Biological Functions* , 2007, Journal of Biological Chemistry.

[20]  W. Gong,et al.  CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. , 2007, Cancer letters.

[21]  Junichi Eguchi,et al.  Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models , 2007, Journal of Translational Medicine.

[22]  A. Heimberger,et al.  Preferential migration of regulatory T cells mediated by gliomasecreted chemokines can be blocked with chemotherapy , 2007, Cancer Immunology, Immunotherapy.

[23]  Sujit S. Prabhu,et al.  Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy , 2007, Cancer Immunology, Immunotherapy.

[24]  Robert D. Schreiber,et al.  Interferons, immunity and cancer immunoediting , 2006, Nature Reviews Immunology.

[25]  K. Aldape,et al.  Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. , 2006, Cancer research.

[26]  A. Gambotto,et al.  Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. , 2006, Cancer research.

[27]  W. Zou.  Regulatory T cells, tumour immunity and immunotherapy , 2006, Nature Reviews Immunology.

[28]  J. Blakely.  Polymorphisms associated with asthma are inversely related to glioblastoma multiforme. , 2006, Cancer research.

[29]  D. Largaespada,et al.  Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  L. Kaiser,et al.  Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity , 2005, Clinical Cancer Research.

[31]  R. Schreiber,et al.  A critical function for type I interferons in cancer immunoediting , 2005, Nature Immunology.

[32]  Douglas F. Easton,et al.  Association studies for finding cancer-susceptibility genetic variants , 2004, Nature Reviews Cancer.

[33]  K. Hess,et al.  Glutathione S-Transferase Polymorphisms and Survival in Primary Malignant Glioma , 2004, Clinical Cancer Research.

[34]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[35]  B. Scheithauer,et al.  A phase III study of radiation therapy plus carmustine with or without recombinant interferon‐α in the treatment of patients with newly diagnosed high‐grade glioma , 2001 .

[36]  B. Moss,et al.  gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand , 1998, The Journal of experimental medicine.

[37]  A. Ommaya,et al.  Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. , 1996, Neurosurgery.

[38]  M. Toda,et al.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.

[39]  T. Malek,et al.  Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. , 1993, Journal of immunology.

[40]  P. Leder,et al.  An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. , 1992, Science.

[41]  F. Ruscetti.  Biology of interleukin-2 , 1984, Survey of immunologic research.

[42]  N. Sobol,et al.  Preliminary results , 2020, Asymptotic Analysis of Random Walks: Light-Tailed Distributions.